Controversies on Lung Cancer: Pros and Cons (Section Chairs: Suresh Senan, Helmut H. Popper)
Rebuttal from Dr Nestle and Dr Belderbos
Abstract
We fully agree that in a case when a patient with a T2N0M0 NSCLC central in the hilum has no other curative treatment option and is not eligible for conventionally fractionated radiotherapy, we can discuss with him/her the potential risk of SBRT and the weakness of the available data and may offer this treatment when the patient agrees to bear this risk.
